Compare
Faeth Therapeutics, Inc. vs CervoMed Inc. vs Gain Therapeutics, Inc. vs Moleculin Biotech, Inc.
| Latest fiscal year | Faeth Therapeutics, Inc. FTH | CervoMed Inc. CRVO | Gain Therapeutics, Inc. GANX | Moleculin Biotech, Inc. MBRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $4.01M | n/a | $0 |
| Revenue growth (YoY) | n/a | -58.9% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -706.2% | n/a | n/a |
| Net margin | n/a | -673.1% | n/a | n/a |
| Net income | -$21.09M | -$26.97M | -$20.16M | -$33.56M |
| EPS (Diluted) | -$16.72 | n/a | -$0.61 | n/a |
| Operating cash flow | -$20.45M | -$23.45M | -$18.47M | -$22.73M |
| Free cash flow | -$20.47M | n/a | n/a | -$22.73M |
| Cash & equivalents | $8.67M | $8.24M | $20.84M | $8.88M |
| Total assets | $22.90M | $22.88M | $22.82M | $22.13M |
| Total liabilities | $4.31M | $4.66M | $4.25M | $7.12M |
| Shareholders' equity | $18.59M | $18.22M | $18.56M | $15.01M |
| Return on year-end equity | -113.4% | -148.0% | -108.6% | -223.6% |
| Shares outstanding | 1.26M | 9.25M | 42.07M | 3.20M |
Revenue, most recent five fiscal years
| Fiscal year | Faeth Therapeutics, Inc. | CervoMed Inc. | Gain Therapeutics, Inc. | Moleculin Biotech, Inc. |
|---|---|---|---|---|
| Latest | n/a | $4.01M Ended 2025-12-31 | $55.2K Ended 2023-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $9.74M Ended 2024-12-31 | $140.1K Ended 2022-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $7.14M Ended 2023-12-31 | $165.0K Ended 2021-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $28.9K Ended 2020-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |